AlphaGen Therapeutics develops targeted radioligand therapies using next-generation Pb-212 isolation technology to enhance the therapeutic window and minimize off-target radiation in cancer treatment. The company aims to improve patient outcomes by providing effective radiopharmaceuticals with broader hospital access and a reliable supply of alpha-emitting isotopes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments often struggle to selectively target tumor cells, leading to off-target radiation and systemic toxicities that limit the therapeutic window and hinder treatment efficacy. The limited availability and high activity of certain alpha-emitting isotopes also pose challenges for broader hospital access and widespread adoption of radioligand therapies.
Solution
AlphaGen Therapeutics is developing a new class of targeted radioligand therapies (RLTs) using Pb-212, an alpha-emitting isotope, to selectively deliver radiation to cancer cells while minimizing damage to healthy tissue. Their next-generation Pb-212 isolation technology enhances the therapeutic window, improves treatment effectiveness, and enhances the quality of life for patients. By leveraging abundant raw material supply and lower radiation activity, AlphaGen aims to provide effective radiopharmaceuticals with broader hospital access and improved market reach.
Target Audience
AlphaGen's primary customers are biotech and pharmaceutical companies, academic research institutions, and health systems focused on cancer treatment and radiopharmaceutical development.
Features
- Next-generation Pb-212 isolation technology for radioligand therapy development
- Development of both alpha and beta radioligand therapies
- Improved therapeutic window due to decreased off-target radiation
- Abundant raw material supply from existing stockpiles of Pb-212
- Lower radiation activity enabling broader hospital and market access